Cleveland Clinic Abu Dhabi: A New Era of Cardiac Excellence

By HEOR Staff Writer

November 5, 2023

A Landmark Achievement in Healthcare

The Department of Health – Abu Dhabi (DoH) has declared Cleveland Clinic Abu Dhabi, a component of the M42 network, as a Centre of Excellence (CoE) for Adult Cardiac Surgery (ACS). This significant announcement is a testament to Abu Dhabi’s commitment to delivering world-class healthcare services to its community and reinforces its standing as a leading healthcare destination.

Centre of Excellence for Adult Cardiac Surgery: A New Standard in Cardiac Care

As an ACS CoE, Cleveland Clinic Abu Dhabi offers a comprehensive range of cardiac surgery and structural heart disease interventions. These services are provided by a team of highly experienced cardiologists and some of the world’s most reputable surgeons. The Clinic boasts dedicated cardiac surgery ICU facilities and cardiac operating rooms, supported by core services that include multidisciplinary cardiovascular medicine, interventional cardiology, electrophysiology, and a pioneering structural heart programme.

H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, emphasised the importance of the CoE programme in elevating healthcare outcomes and increasing competitiveness across the sector. She expressed delight at the announcement and looked forward to the continuous contributions from partners to enhance the healthcare sector’s excellence.

Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi and Managing Director and Group Chief Executive Officer of M42, highlighted the Clinic’s establishment as a regional and global benchmark for complex care. He reiterated their commitment to excellence and the vision of providing world-class complex care to patients in the UAE and across the region.

Reference url

Recent Posts

Inflation Reduction Act Impact on Clinical Trial Investment Trends

By João L. Carapinha

March 26, 2026

The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles
Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector
South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...